Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors

doi:10.3748/wjg.v32.i34.119567

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 34

This Article

(5)

(4)

(0)

(13)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 14, 2026; 32(34): 119567
Published online Sep 14, 2026. doi: 10.3748/wjg.v32.i34.119567

Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors

Rui Guo, Meng Gao

Rui Guo, Department of Laboratory Medicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou 462000, Henan Province, China

Meng Gao, Department of Anesthesiology and Perioperative Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

Author contributions: Guo R initiated research, conducted the collation and statistical analysis, wrote the original manuscript and revised the paper; Gao M designed the experiments, conducted clinical data collection, performed postoperative follow-up and recorded the data; all authors read and approved the final manuscript.

AI contribution statement: We confirm that no AI tools were used at any stage, including in the preparation of the response to reviewers. All content of the manuscript and the rebuttal letter was fully written, reviewed, and approved by the authors.

Institutional review board statement: This study was approved by the Ethics Committee of Henan Provincial People’s Hospital, No. 2024-1-112.

Informed consent statement: The Ethics Committee agrees to waive informed consent.

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

Data sharing statement: All data generated or analyzed during this study are included in this published article.

Corresponding author: Rui Guo, Department of Laboratory Medicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Road, Jinshui District, Zhengzhou 462000, Henan Province, China. guorui2460@163.com

Received: March 3, 2026
Revised: March 25, 2026
Accepted: May 11, 2026
Published online: September 14, 2026
Processing time: 168 Days and 18.3 Hours

Core Tip

Core Tip: The systemic immune-inflammation index (SII), calculated from routine blood counts, integrates neutrophils, lymphocytes, and platelets to reflect the host immune-inflammatory balance. This retrospective study of 238 advanced gastric cancer patients treated with immune checkpoint inhibitors demonstrates that a high baseline SII (≥ 593.995) independently predicts poor progression-free survival and lower disease control rates. Combining SII with clinical parameters significantly improves predictive accuracy for early progressive disease, suggesting SII as a practical and accessible biomarker for risk stratification in immune checkpoint inhibitors-treated gastric cancer.